In Group C, adult patients with IDH1 wild-type AA or glioblastoma will receive zotiraciclib at recurrence after receiving radiation plus concurrent TMZ followed by adjuvant TMZ [90]. The gene discussed is IDH1; the disease is glioblastoma.